期刊文献+

白细胞介素-12基因修饰的树突状细胞瘤苗小鼠体内抗肝癌的作用 被引量:1

Antitumor activities in vivo of Interleukin-12 gene modified dendritic cells in murine models
原文传递
导出
摘要 目的:在小鼠H22肝癌模型中研究mIL-12基因修饰的及酸洗脱肽致敏的树突状细胞(dendritic cells,DC)瘤苗体内诱导抗肝癌免疫的能力。方法:用mIL-12的重组腺病毒Ad mIL-12及对照病毒AdBGFP转染从小鼠骨髓细胞中诱导培养的DC。弱酸洗脱小鼠肝癌细胞株H22表面的抗原肽并致敏mIL-12基因转染组及对照病毒转染组DC。免疫小鼠后观察不同处理的DC瘤苗对小鼠H22皮下移植瘤成瘤情况及肿瘤生长的影响。 结果:mIL-12基因修饰的及酸洗脱肽致敏的DC瘤苗明显抑制小鼠H22皮下移植瘤的生长,瘤重与对照组相比差别有显著意义(P<0.05=。 结论:以mIL-12基因修饰且以酸洗脱肽致敏的DC瘤苗可在小鼠肝癌模型中诱导较强的抗肿瘤免疫,这将为肝癌的防治提供可行的DC瘤苗制备方案。 Objective: To study the antitumor activities of the mIL-12 transfected and acid-eluted peptide sensitized dendritic cells (DC) in murine H22 liver cancer model. Methods: The murine bone marrow derived DC were transfected with the recombinant adenovirus (Ad mIL-12) containing the mIL-12 gene and control virus AdBGFP. The peptides on the surface of the murine H22 cell line were eluted with mild acid buffer and then sensitized the transfected DC. The experimental animals were immunized with the differently disposed DC and the state of tumorgenesis and tumor growth was observed. Results: The tumor growth and weight in the group immunized with mIL-12 transfected and acid-eluted peptide sensitized DC were significantly lower than those of control group (P<0.05). Conclusion: The mIL-12 transfected and acid-eluted peptide sensitized DC can induce obvious antitumor activities in the murine liver cancer models and may suggest new strategies for constructing new type of DC vaccine for liver cancer.
出处 《中华肝脏病杂志》 CAS CSCD 2000年第6期350-351,共2页 Chinese Journal of Hepatology
基金 国家自然科学基金!(39770826)
关键词 肝细胞癌 树突状细胞 白细胞介素-12 瘤苗 Carcinoma, hepatocellular Dendritic cells Interleukin-12 Tumor vaccine`
  • 引文网络
  • 相关文献

参考文献2

二级参考文献4

共引文献10

同被引文献28

  • 1Jenne L,Arrighi JF,Jonuleit H,et al.Dendritic cells containing apoptotic melanomacells prime human CD 8 T cells for efficienttumor cell lysis[J].CancerRes,2000,60(16):4446-4452.
  • 2Punt CJ,de Vries IJ,Mulders PF,et al.Immunology in medical practice.XXV.Use ofdendritic cells in the immunotherapy of cancer[J].Ned TijdschrGeneeskd,1999,143(48):2408-2414.
  • 3X Cao,W Zhang,J Wang,et al.Therapy of established tumour with a hybrid cellularvaccine generated by using granulocyte macrophage colony stimulating factor geneticallymodified dendritic cells[J].Immunology,1999,97:616-625.
  • 4Weiping Zhang,Long He,ZhengLong Yuan,et al.Enhanced therapeutic efficacy of tumorRNA pulsed dendritic cells aftergenetic modification with lymphotactin[J].Human GeneTherapy,1999,10:1151-1161.
  • 5Mule JJ.Tumor vaccine strategiesthat employ dendritic cells and tumor lysates:experimental and clinical studies[J].ImmunolInvest,2000:29(2):127-129.
  • 6Ranieri E,Kierstead LS,Zarour H,et al.Dendritic cell/peptide cancervaccines:clinical responsiveness and epitope spreading [J]. ImmunolInvest,2000,29(2):121-125.
  • 7Kugler A,Stuhler G,Walden P,et al.Regression of human metastatic renal cellcarcinoma after vaccination with tumor cell dendritic cell hybrids[J].NatMed,2000,6(3):332-336.
  • 8Sauter B,Albert ML,Francisco L,et al.Consequences of cell death:exposure tonecrotic tumor cells,but not primary tissue cellsor apoptotic cells,induces the maturationof immunostimulatory dendritic cells[J].J Exp Med,2000,191(3):423-434.
  • 9Holtl L,Rieser C,Papesh C,et al.Cellular and humoral immune responses in patientswith metastatic renal cell carcinoma aftervaccination with antigen pulsed dendritic cells[J].J Urol,1999,161(3):777-782.
  • 10Rieser C,Ramoner R,Holtl L,et al.Mature dendritic cells induce T helper type ldominant immune responses inpaticnts with metastatic renal cell carcinoma[J].UrolInt,1999,63(3):151-159.

引证文献1

二级引证文献2

;
使用帮助 返回顶部